VIDA®

Transforming Pulmonary Care in the Age of Intelligence

Susan Wood, Ph.D., CEO

susan@vidalung.ai

612.247.2889

@ceo_vida

VIDA Transforms Lung Care

In the Age of Intelligence

USES IMAGING-BASED AI and PREDICTIVE ANALYTICS

To Uniquely Profile and Manage the Patient with or at Risk of Lung Disease

To Provide and Deliver Precision Healthcare

© 2019 VIDA Diagnostics, Inc. | vidalung.ai

Transforming Pulmonary Care → Subjective to Objective and Repeatable

Non-optimal measures

LungPrint® by VIDA

- **PRECISE**
- **PERSONALIZED**
- **PREDICTIVE**



© 2019 VIDA Diagnostics, Inc. | vidalung.ai

Select VIDA Partners

Academic Partners

UBC
Washington University in St. Louis
The University of Iowa
Stanford Health Care
Universität Heidelberg Zukunft seit 1386
Columbia University
Ryerson University
University of Washington
NYU
robarts Research
McGill University
Providence Healthcare Network

Preclinical Programs

GRIFOLS
AstraZeneca
NUVAIRA
gsk
BIOCLINICA

Channel Partners

NUANCE
TeraRecon
BRONCUS
OLYMPUS
Your Vision, Our Future

© 2018 VIDA Diagnostics, Inc. | www.vidadiagnostics.com

VIDA's Curated Library of Lung Insights

70+ Trials, Ongoing Data Collection

Hundred Thousands Patient Data and MetaData

30+ Imaging Clinically Validated Biomarkers

1.2B+ Precise Biomarker Measures

26T+ of Comparative Precision Measures

VIDA Curated Library of Patients with/at risk of Lung Disease

© 2018 VIDA Diagnostics, Inc. | www.vidadiagnostics.com

Delivers True Personalized Medicine

+

=

LungPrint

VIDA Curated Library of Patients with/at risk of Lung Disease

VIDA Trade Secret AI Processing

Your Unique Lung Profile

© 2018 VIDA Diagnostics, Inc. | www.vidadiagnostics.com

Clinical Readiness for AI



Clinical Relevancy



Clinical Validation

Workflow Integration

Return on Investment $

[Signify, 2019]

© 2018 VIDA Diagnostics, Inc. | www.vidadiagnostics.com

Clinical Relevancy





© 2018 VIDA Diagnostics, Inc. | www.vidadiagnostics.com

Clinical Relevancy

Respiratory Trials are Long and Expensive

Clinical Relevancy

REDUCED TRIAL COSTS[1]



SHORTED TIMELINES[1]



© 2018 VIDA Diagnostics, Inc. | www.vidadiagnostics.com

Clinical Validation

Clinical Validation



AstraZeneca

MESA

SPIROMICS

CanCOLD

200+
Publications

© 2018 VIDA Diagnostics, Inc. | www.vidadiagnostics.com

Workflow Integration

Workflow Integration

NUANCE

terarecon

© 2018 VIDA Diagnostics, Inc. | www.vidadiagnostics.com

Return on Investment



1.2 mm lumen diameter



2.5 mm lumen diameter

© 2018 VIDA Diagnostics, Inc. | www.vidadiagnostics.com

Return on Investment

33% Time Savings





© 2018 VIDA Diagnostics, Inc. | www.vidadiagnostics.com

Return on Investment

Triaging the right patients to trials increases success likelihood and shortens trials



~$14M
Saved/trial

LungPrint Value

The Impact of Selection Biomarkers



© 2018 VIDA Diagnostics, Inc. | www.vidadiagnostics.com

AI-Driven Advanced Visualization

Airway Involvement Unclear

Full View of Airways

Clear Airway Access to Lesion



Hyperion View

© 2018 VIDA Diagnostics, Inc. | www.vidadiagnostics.com

VIDA built on the Pillars of AI

- Lung Disease a high economic burden
- Treatment Opportunities Increasing

- 70+ Trials
- 200+ Publications

- Workflow Integration with Strategic Partners
- AI Marketplaces for Hosting AI on the Rise

- Radiology and Clinical Productivity
- Precision Treatment Development and Validation

© 2018 VIDA Diagnostics, Inc. | www.vidadiagnostics.com